Back to companies

Reata Pharmaceuticals Inc: Overview

Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Reata Pharmaceuticals Inc (Reata) is a clinical-stage biopharmaceutical company. It develops innovative medicines for the treatment of serious and life-threatening diseases. The company's clinical candidates include bardoxolone methyl and omaveloxolone, which target Nrf2, a transcription factor, for restoring mitochondrial function, reducing oxidative stress, and resolving inflammation. Its products also include HSP90 modulators, RTA 901, RORγt inhibitors, and RTA 1701. Reata is evaluating bardoxolone methyl in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), alport syndrome and other kidney diseases; and omaveloxolone in Friedreich’s ataxia. The company works in partnership with academics, biotechnology, and pharmaceutical companies to develop technologies. It has operations in the US, the UK, Ireland, Australia and Switzerland. Reata is headquartered in Plano, Texas, the US.

Headquarters United States of America

Address 5320 Legacy Dr, Plano, Texas, 75024-3127


Telephone 1 972 8652219

No of Employees 346

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange RETA (NASD)

Revenue (2021) $11.5M 27.4% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -20% (2021 vs 2020)

Market Cap* $1.2B

Net Profit Margin (2021) XXX 5.8% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

50+

Clinical Trials

Determine Reata Pharmaceuticals Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Reata Pharmaceuticals Inc’s relevant decision makers and contact details.

30+

Catalyst Calendar

Proactively evaluate Reata Pharmaceuticals Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Pipeline Drugs

Identify which of Reata Pharmaceuticals Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

18+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

5

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products
Bardoxolone Methyl and Omaveloxolone
RTA 901
RTA 1701
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Regulatory Approval In February, the company announced the completion of the rolling submission for omaveloxolone for the treatment of patients with Friedreich’s ataxiato with the U.S. Food and Drug Administration.
2022 Regulatory Approval In February, the company announced the U.S. Food and Drug Administration issued a Complete Response Letter for the New Drug Applicatio for bardoxolone methyl (“bardoxolone”) to treat patients with chronic kidney disease.
2022 Regulatory Approval In January, the company initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for omaveloxolone for the treatment of patients with Friedreich’s ataxia.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Reata Pharmaceuticals Inc Bayer AG Sanofi AstraZeneca Plc Eli Lilly and Co
Headquarters United States of America Germany France United Kingdom United States of America
City Plano Leverkusen Paris Cambridge Indianapolis
State/Province Texas Nordrhein-Westfalen - Cambridgeshire Indiana
No. of Employees 346 100,753 95,442 83,100 35,000
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Warren Huff Chairman; Chief Executive Officer Executive Board 2002 68
Manmeet S. Soni Chief Operating Officer; President; Chief Financial Officer Senior Management 2022 44
Bhaskar Anand Chief Accounting Officer; Vice President Senior Management - -
Michael D. Wortley Executive Vice President; Chief Legal Officer Senior Management 2015 74
Samina Khan Senior Vice President; Chief Medical Officer Senior Management 2020 57
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer